Orum Therapeutics Appoints Dr. Sang Hyun Lee as Vice President, Research Site Head, Korea, to Accelerate Innovation in Novel Degrader-Antibody Conjugates
BOSTON, USA & DAEJEON, South Korea, April 21, 2025 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Sang Hyun (Shawn) Lee, Ph.D., as Vice President, Research Site Head, Korea. Dr. Lee brings over two decades of scientific leadership in cancer biology and drug discovery, including extensive experience in the discovery and development of protein degrader technologies. In this role, he will serve as a key bridge between Orum’s research teams in Korea and the U.S. to accelerate progress on the company’s Dual-Precision Targeted Protein Degradation (TPD²®) approach.
“This strategic appointment reflects Orum’s ongoing commitment to building global leadership in TPD-based therapeutics,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum Therapeutics. “Dr. Lee’s deep expertise in PROTACs, DACs, and TPD biology, combined with his leadership in bringing multiple novel molecules from discovery into the clinic, will be instrumental as we continue to develop next-generation degrader-antibody conjugate platforms and expand our pipeline.”
“I am excited to join Orum at this important time,” said Dr. Lee. “Orum is at the forefront of integrating antibody targeting with protein degrader technology to overcome limitations of traditional therapies. I look forward to working with the team to expand the potential of TPD payloads and help bring transformative therapies to patients.”
Previously, Dr. Lee held senior research leadership roles at Prelude Therapeutics and Arvinas, where he helped advance targeted protein degrader programs. He also held discovery leadership positions at Incyte Corporation and began his research career at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Lee holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas and completed postdoctoral research at Dana-Farber Cancer Institute. He has co-authored more than 20 peer-reviewed publications and led or co-led multiple successful Investigational New Drug (IND) submissions to the U.S. FDA.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a clinical-stage biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to improve cancer treatment for more patients. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the pace of progress in developing Orum’s technologies; the development of new payload platforms and the expansion of Orum’s pipeline; the potential for filing of IND applications and their approval; the potential initiation of clinical trials; and potential benefits to patients are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: Kayla (Gyebang) Mo, Director, IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
